Treatment of arterial hypertension in patients with severe obesity
More details
Hide details
Department of Cardiology and Internal Medicine, School of Medicine, Collegium Medicum, University of Warmia and Mazury in Olsztyn, Poland
Department of Psychology and Sociology of Health and Public Health, School of Public Health, Collegium Medicum, University of Warmia and Mazury in Olsztyn, Poland
Submission date: 2023-10-17
Final revision date: 2023-11-27
Acceptance date: 2023-11-29
Online publication date: 2023-12-30
Corresponding author
Beata Moczulska   

Department of Cardiology and Internal Medicine, School of Medicine, Collegium Medicum, University of Warmia and Mazury in Olsztyn, Warszawska 30, 10-082 Olsztyn, Poland.
Acta Elbingensia 2023;50(1):19-25
Obesity is one of the most important cardiovascular risk factors for mortality. It increases the risk of developing hypertension and influences the response to antihypertensive drugs. Ambulatory blood pressure measurement (ABPM) is a tool for a detailed analysis of mean blood pressure values and assessing the blood pressure (BP) profile during the night with the daily values and optimal treatment determination.

The study aimed to evaluation the type of antihypertensive drugs and control assessment of hypertension based on ABPM in patients with severe obesity.

Material and methods:
The study group consisted of 129 overweight and obese patients (group 1: BMI < 40 kg/m2; group 2: BMI ≥ 40 kg/m2).They were interviewed, taking into account the antihypertensive drugs taken. We divided drugs into 5 groups: beta-blockers, angiotensin converting enzyme inhibitors (ACE-I) / angiotensin II receptor blockers (ARB), diuretics, calcium channel blockers and others. Mean systolic BP and diastolic BP from the day, day and night, mean heart rate from day to day was assessed based on ABPM.

Results and discussion:
The most frequently administered drugs in both groups were ACE-I/ARB. The second most often taken drug was β-blocker and diuretics. Group 1 was significantly older than group 2. Based on the analysis, HR level was significantly dependent on age, BMI, and diabetes. The systolic BP and diastolic BP level was dependent on age and sex.

Only a combination of individually designed pharmacological therapy with personalized dietary interventions, regular exercise, cognitive behavioral therapy, and bariatric interventions, when needed, could guarantee the final success. ABPM should be used routinely in every patients to control assessment of hypertension.

Not declared.
Not declared.
World Health Organization. Obesity and Overweight. Fact Sheets Obesity and Overweight. 2021. Aaccessed: 2023-01-27.
Aguilar-Gallardo JS, Romeo FJ, Bhatia K, Correa A, Mechanick JI, Contreras JP. Severe obesity and heart failure. Am J Cardiol. 2022;177:53–60.
Kelly T, Yang W, Chen CS, Reynolds K, He J. Global burden of obesity in 2005 and projections to 2030. Int J Obes (Lond). 2008;32(9):1431–1477.
Garvey WT, Mechanick JI, Brett EM, et al.; Reviewers of the AACE/ACE Obesity Clinical Practice Guidelines. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical cractice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22(Suppl 3):1–203.
Whitlock G, Lewington S, Sherliker P, et al.; Prospective Studies Collaboration. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009;373(9669):1083–1096.
Di Angelantonio E, Bhupathiraju SN, Wormser D, et al.; Global BMI Mortality Collaboration. Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents. Lancet. 2016;388(10046):776–786. doi: 10.1016/S0140-6736(16)30175-1.
Aune D, Sen A, Prasad M, et al. BMI and all cause mortality: Systematic review and non-linear dose-response meta-analysis of 230 cohort studies with 3.74 million deaths among 30.3 million participants. BMJ. 2016;353:i2156.
Stamler R, Stamler J, Riedlinger WF, Algera G, Roberts RH. Weight and blood pressure. Findings in hypertension screening of 1 million Americans. JAMA. 1978;240(15):1607–1610.
Dyer AR, Elliott P, Shipley M. Body mass index versus height and weight in relation to blood pressure. Findings for the 10,079 persons in the INTERSALT Study. Am J Epidemiol. 1990 Apr;131(4):589–596.
Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. JAMA. 1999;282(16):1523–1529.
World Health Organization. The challenge of obesity in the WHO European Region. Fact sheet EURO 2005;13:1–4.2.
Stergiou GS, Palatini P, Parati G, et al.; European Society of Hypertension Council and the European Society of Hypertension Working Group on Blood Pressure Monitoring and Cardiovascular Variability. 2021 European Society of Hypertension practice guidelines for office and out-of-office blood pressure measurement. J Hypertens. 2021;39(7):1293–1302.
Aneja A, El-Atat F, McFarlane SI, Sowers JR. Hypertension and obesity. Recent Prog Horm Res. 2004;59:169–205.
Wenzel UO, Benndorf R, Lange S. Treatment of arterial hypertension in obese patients. Semin Nephrol. 2013;33(1):66–74.
Coatmellec-Taglioni G, Ribière C. Factors that influence the risk of hypertension in obese individuals. Curr Opin Nephrol Hypertens. 2003;12(3):305–308.
Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018;36(10):1953–2041.
Grassi G, Calhoun DA, Mancia G, Carey RM. Resistant hypertension management: comparison of the 2017 American and 2018 European high blood pressure guidelines. Curr Hypertens Rep. 2019;21(9):67.
Haddadin F, Sud K, Munoz Estrella A, et al. The prevalence and predictors of resistant hypertension in high‐risk overweight and obese patients: A cross‐sectional study based on the 2017 ACC/AHA guidelines. J Clin Hypertens. 2019;21(10):1507–1515.
Tepe D, Yılmaz S. Is office blood pressure measurement reliable in obese adolescents? Diabetes Metab Syndr Obes. 2021;14:3809–3817.
Palatini P, Reboldi G, Beilin LJ, et al. Prognostic value of ambulatory blood pressure in the obese: the Ambulatory Blood Pressure‐International Study. J Clin Hypertens (Greenwich). 2016;18(2):111–118.
Hales CM, Carroll MD, Fryar CD, et al. Prevalence of Obesity and Severe Obesity Among Adults: United States, 2017–2018. NCHS Data Brief, no 360. Hyattsville, MD: National Center for Health Statistics. 2020:1–8. Accessed: 2023-12-19.
Grassi G, Biffi A, Seravalle G, et al. Sympathetic neural overdrive in the obese and overweight state. Hypertension. 2019;74(2):349–358.
Reisin E, Graves JW, Yamal JM, et al. Blood pressure control and cardiovascular outcomes in normal-weight, overweight, and obese hypertensive patients treated with three different antihypertensives in ALLHAT. J Hypertens. 2014;32(7):1503–1513.
Parikh JS, Randhawa AK, Wharton S, Edgell H, Kuk JL. The association between antihypertensive medication use and blood pressure is influenced by obesity. J Obes. 2018;2018:4573258.
Cataldi M, di Geronimo O, Trio R, et al. Utilization of antihypertensive drugs in obesity-related hypertension: a retrospective observational study in a cohort of patients from Southern Italy. BMC Pharmacol Toxicol. 2016;17:9.
Journals System - logo
Scroll to top